Protalix Biotherapeutics Inc Share Price TEL AVIV STOCK EXCHANGE
Equities
US74365A1016
Biotechnology & Medical Research
Sales 2024 * | 74.06M 27.51B 5.9B | Sales 2025 * | 127M 47.31B 10.14B | Capitalization | 83.58M 31.05B 6.66B |
---|---|---|---|---|---|
Net income 2024 * | 17M 6.32B 1.35B | Net income 2025 * | 70M 26B 5.58B | EV / Sales 2024 * | 1.13 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.66 x |
P/E ratio 2024 * |
5.43
x | P/E ratio 2025 * |
1.41
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.27% |
Latest transcript on Protalix Biotherapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 29/06/19 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 21/07/19 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 04/07/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 30/11/19 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 30/11/19 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 31/10/14 |
1st Jan change | Capi. | |
---|---|---|
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |